Bakhiet Tasneem Elghazali, Ansari Abdus Samad, Williams Gwyn Samuel, Awad Mahmoud Husseiny, Thomas Alistair
Swansea Eye Unit, Singleton Hospital, University of Swansea, Swansea, Wales, UK.
Clin Ophthalmol. 2025 May 30;19:1743-1749. doi: 10.2147/OPTH.S508547. eCollection 2025.
Dry Eye Syndrome (DES) significantly impacts vision-related quality of life and poses a substantial financial burden in ophthalmology practice globally. Projected expenditure on DES treatments is estimated to exceed 6.6 billion USD by 2027. The Meibopatch (VISUfarma International, Valbonne, France) represents one of the latest devices designed to enhance treatment adherence and aid in managing Dry Eye Syndrome (DES). However, its long-term acceptance and efficacy among patients with posterior blepharitis, a condition closely linked with Meibomian gland dysfunction (MGD), has yet to be demonstrated.
Patients with symptomatic non-responsive blepharitis were enrolled during clinic visits and asked to self-administer Meibopatch treatment for four weeks. The ocular surface disease index (OSDI) questionnaire was utilized to evaluate symptoms both at baseline and following the four-week treatment period. Supplementary assessments on acceptability and tolerability were conducted through post-treatment questionnaires.
A total of 43 patients were recruited. The baseline pre-treatment OSDI score ± SD (Standard Deviation) was 47.9±16.4, while the post-treatment OSDI value + SD was 37.7±14.9. Analysis revealed a significant mean difference between pre- and post-treatment OSDI scores (p=0.0005), indicating notable symptomatic improvement over the assessment duration. However, the findings diverged from evaluations of acceptability and overall patient satisfaction with the Meibopatch.
The results suggest that Meibopatch represents a safe therapeutic option for managing DES. However, the controversy arises from the incongruence between the substantial reduction in symptoms noted from the OSDI scores and the reported patient outcomes regarding satisfaction and effectiveness. Future efforts should focus on validating the OSDI in blepharitis patients and establishing patient-centered outcomes in the realm of DES.
干眼症（DES）严重影响与视力相关的生活质量，在全球眼科医疗实践中造成了巨大的经济负担。预计到2027年，DES治疗的支出将超过66亿美元。美泊贴片（VISUfarma International，法国瓦尔博讷）是旨在提高治疗依从性并辅助管理干眼症（DES）的最新设备之一。然而，其在睑缘炎患者（一种与睑板腺功能障碍（MGD）密切相关的病症）中的长期接受度和疗效尚未得到证实。
有症状且无反应性睑缘炎的患者在门诊就诊时被纳入研究，并被要求自行使用美泊贴片治疗四周。使用眼表疾病指数（OSDI）问卷在基线和四周治疗期后评估症状。通过治疗后问卷对可接受性和耐受性进行补充评估。
共招募了43名患者。治疗前OSDI评分±标准差（SD）的基线值为47.9±16.4，而治疗后OSDI值+SD为37.7±14.9。分析显示治疗前和治疗后OSDI评分之间存在显著的平均差异（p=0.0005），表明在评估期间症状有明显改善。然而，研究结果与对美泊贴片的可接受性和患者总体满意度的评估存在差异。
结果表明美泊贴片是管理DES的一种安全治疗选择。然而，争议源于OSDI评分显示的症状大幅减轻与报告的患者满意度和有效性结果之间的不一致。未来的工作应侧重于验证睑缘炎患者的OSDI，并在DES领域建立以患者为中心的结果。
